Literature DB >> 28990532

A Novel SCN9A Mutation (F826Y) in Primary Erythromelalgia Alters the Excitability of Nav1.7.

B Wu1,2, Y Zhang3, H Tang1, M Yang1, H Long4, G Shi1, J Tang1,5, X Shi1.   

Abstract

BACKGROUND: Primary erythromelalgia (PE) is a dominant inherited disorder characterized by recurrent pain, redness, and warmth of the extremities that is caused by gain-of-function mutations in Nav1.7 encoding gene SCN9A. Most of the PE-causing mutations of Nav1.7 have been shown to be able to render Nav1.7-expressing cells hyperexcitable, however in most PE cases the symptoms are refractory to treatment with sodium channel blockers and the mechanism underlying the intractability has not been clearly clarified.
OBJECTIVE: To identify the mutation of SCN9A in a Chinese Han family with typical symptoms of PE and study the electrophysiological effect of the identified mutation.
METHODS: A Chinese Han family with typical symptoms of PE was collected and the proband's response to treatment was recorded. All the exons and flanking intronic sequences of SCN9A were amplified with PCR and sequenced. Several online programs were used to predict the damaging effect of variants. The functional effect of variants was studied by voltage-clamp analysis in CHO-K1 cells.
RESULTS: The PE symptoms of the proband are refractory to all kinds of reported medications. Sequence analysis of SCN9A showed that a novel c.2477T>A (p. F826Y) mutation co-segregated with the disease phenotype. Several online programs predicted that the F826Y mutation has a deleterious effect on the gene product. Voltage-clamp analysis showed that while compared with the wild-type channel, activation of the F826Y mutant channel was shifted by 7.7 mV in a hyperpolarizing direction, whereas steadystate inactivation was shifted by 4.3 mV in a depolarizing direction.
CONCLUSION: A novel disease-causing SCN9A Mutation (F826Y) was identified in a Chinese family with typical PE symptoms refractory to treatment. F826Y of Nav1.7 could render DRG neurons hyperexcitable, contributing to the pathogenesis of PE. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Nav1.7; Primary erythromelalgia; SCN9A; novel mutation; voltage-gated sodium channel; voltageclamp.

Mesh:

Substances:

Year:  2017        PMID: 28990532     DOI: 10.2174/1566524017666171009105029

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  4 in total

Review 1.  Painful and painless mutations of SCN9A and SCN11A voltage-gated sodium channels.

Authors:  Mark D Baker; Mohammed A Nassar
Journal:  Pflugers Arch       Date:  2020-06-29       Impact factor: 3.657

2.  Hydropathicity-based prediction of pain-causing NaV1.7 variants.

Authors:  Makros N Xenakis; Dimos Kapetis; Yang Yang; Monique M Gerrits; Jordi Heijman; Stephen G Waxman; Giuseppe Lauria; Catharina G Faber; Ronald L Westra; Patrick J Lindsey; Hubert J Smeets
Journal:  BMC Bioinformatics       Date:  2021-04-23       Impact factor: 3.169

3.  Engineering Gain-of-Function Analogues of the Spider Venom Peptide HNTX-I, A Potent Blocker of the hNaV1.7 Sodium Channel.

Authors:  Yunxiao Zhang; Qiuchu Yang; Qingfeng Zhang; Dezheng Peng; Minzhi Chen; Songping Liang; Xi Zhou; Zhonghua Liu
Journal:  Toxins (Basel)       Date:  2018-09-04       Impact factor: 4.546

4.  Discovery of a Novel Nav1.7 Inhibitor From Cyriopagopus albostriatus Venom With Potent Analgesic Efficacy.

Authors:  Yunxiao Zhang; Dezheng Peng; Biao Huang; Qiuchu Yang; Qingfeng Zhang; Minzhi Chen; Mingqiang Rong; Zhonghua Liu
Journal:  Front Pharmacol       Date:  2018-10-16       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.